Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19770197 | 0.85 | HTT (0.44) | MEN1HTTKMT2ACA12CA1 | |
| SCHEMBL10266596 | 0.83 | KDM4A (0.44) | KDM4AL3MBTL1RAB9ACA12CA1 | |
| SCHEMBL130176 | 0.83 | PRMT6 (0.47) | KDM4AL3MBTL1MEN1KMT2ACA12 | |
| SCHEMBL31486392 | 0.83 | KDM4A (0.44) | KDM4AL3MBTL1CA12CA1CA2 | |
| SCHEMBL13975464 | 0.82 | KDM4A (0.43) | KDM4AL3MBTL1HTTCA12CA1 | |
| SCHEMBL15184496 | 0.82 | KDM4A (0.43) | KDM4AL3MBTL1CA12CA1CA2 | |
| SCHEMBL4068147 | 0.82 | KDM4A (0.43) | KDM4AL3MBTL1CA12CA1CA2 | |
| SCHEMBL24139881 | 0.81 | KDM4A (0.42) | KDM4AL3MBTL1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL588966 | 0.81 | KDM4A (0.42) | KDM4AL3MBTL1CA12CA1CA2 | |
| SCHEMBL3672962 | 0.81 | TP53 (0.49) | KDM4AL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261328-A1 | AMIDE-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-0979227-B1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6352982-B1 | TREATING DIABETES, OBESITY, OR INVETERATE DIARRHEA IN A MAMMAL WHICH COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF A COMPOUND OF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-0979227-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998047882-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | KDM4A 3217/4885L3MBTL1 393/4885NPC1 620/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KDM4A 2137/4885L3MBTL1 1895/4885NPC1 1006/4885 |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | KDM4A 2075/4885L3MBTL1 4394/4885NPC1 2096/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | KDM4A 3217/4885L3MBTL1 393/4885NPC1 620/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | KDM4A 3125/4885L3MBTL1 482/4885NPC1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.